Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07294274
Recruiting Observational

Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke

NCT07294274 · tracked via the Priya Life Science China tracker
Sponsor
Min Su
Phase
Observational
Started
2025-11-01
Last updated
2026-02-05

Condition(s) studied

Post-stroke Depression

Investigational drug(s) / intervention(s)

Group patients based on whether they have been diagnosed with PSD.

Group patients based on whether they have been diagnosed with PSD.: Group patients based on whether they have been diagnosed with PSD.

Study summary

Post-stroke depression (PSD) is the most common neuropsychiatric disorder after a stroke, with an incidence rate of 20% to 60%. PSD is not only associated with higher mortality rates, poorer recovery, more obvious cognitive impairments, greater economic burdens, and lower quality of life, but also brings additional medical expenses and care pressure to families. Society also needs to bear higher medical costs. Currently, the early diagnosis of PSD is difficult, which may lead to poor prognosis after stroke. This study aims to utilize machine learning technology to integrate multi-dimensional indicators of patients with ischemic stroke, establish a risk prediction model for PSD, and assist in early, accurate, and individualized assessment of PSD risk in clinical practice.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with acute ischemic stroke; * Admission within 7 days of symptom onset; * The patient and/or the family members sign a written informed consent form. Exclusion Criteria: * Confusion of consciousness,severe cognitive impairment, etc * Individuals with a history of depression, schizophrenia, bipolar disorder, etc; * Individuals unable to participate in neuropsychological examinations due to hearing im pairments, lack of coordination, or neurological deficits, including se vere aphasia.

Primary outcome measure(s)

  • The number of post-stroke depression (PSD) that occurs 3 months after stroke — 3 months after stroke

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Chongqing Medical University Chongqing China Recruiting

More Min Su trials in China

Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study Recruiting
Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring Recruiting
Quantitative Consciousness Index Monitoring (qNOX) of Sedation During Endoscopy Recruiting

Other trials for the same condition

Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07294274 on ClinicalTrials.gov ↗ ← All trials in China